In a recent review article pub­lished in the journal Clinical Cancer Re­search, two myeloma experts from the Dana-Farber Cancer In­sti­tute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treat­ment of mul­ti­ple myeloma.

In their article, the experts discuss newer ther­a­pies that appear to be promising in clin­i­cal and pre­clin­i­cal stud­ies.

According to the physicians, com­bi­na­tion ther­a­pies that spe­cif­i­cally target a patient’s ge­netic form of the dis­ease will be re­quired for long-term dis­ease con­trol and ultimately a cure.

Some Historical Perspective

In their review article, Drs. Munshi and …

Combined data from two recent Phase 1 clinical trials suggest that twice-weekly marizomib, with or without low-dose dexamethasone, may be effective for patients with relapsed or refractory multiple myeloma.

Dr. David Vesole from the John Theurer Cancer Center in Hackensack, New Jersey, who was not involved in the study, described marizomib as having “modest activity in relapsed/refractory myeloma.”

Dr. Paul Richardson from the Dana-Farber Cancer Institute in Boston presented the results at the American Society of Hematology (ASH) annual meeting in San Diego last month.

Marizomib (NPI-0052), which is being developed by …

Yesterday was the third day of the American Society of He­ma­tol­ogy (ASH) 2011 Annual Meeting in San Diego, and it was packed full with mul­ti­ple myeloma-related pre­sen­ta­tions. Presentations started early in the morn­ing and con­tinued through the afternoon.

The morn­ing pre­sen­ta­tions about po­ten­tial new myeloma ther­a­pies will be covered in this up­date, and pre­sen­ta­tions from the rest of the day will be covered in addi­tional up­dates.

MLN9708

During the first talk of the day, Dr. Paul Richardson from the Dana-Farber Cancer In­sti­tute in Boston pre­sented re­­sults from a Phase 1 study of …

A new study suggests that NPI-0052 (marizomib), a new product being developed by Nereus Pharmaceuticals, Inc., may be more active and less toxic in patients with relapsed or refractory myeloma despite treatment with Velcade (bortezomib) and other drugs. Researchers presented the preliminary results of the Phase 1 trial on December 7 at the 51st annual meeting of the American Society of Hematology (ASH).

Found in marine bacteria, NPI-0052 acts, like Velcade, as a proteasome inhibitor. Both compounds prevent enzymes in cancer cells that regulate growth from working properly, which …

Description:
Marizomib (NPI-0052, salinosporide A) (news articles) is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells.  Marizomib may be used as an alternative treatment to Velcade (bortezomib), the first approved proteasome inhibitor, because it has shown significant activity …